ended5월 27일· 1 sources
The TIGIT Mirage: Why Pharma’s $100 Billion Bet Turned Into a Cautionary Tale
'제2의 Keytruda'라는 신기루, 수조 원을 삼키고 금기어가 된 TIGIT
Why it matters
The collapse of TIGIT drug trials underscores the immense volatility of immunotherapy R&D, where yesterday’s miracle candidate can quickly become today’s industry-wide stigma. This shift signals a broader trend of cautious skepticism in biotech, forcing firms to re-evaluate how they identify and fund the next generation of cancer treatments.
1
Sources
+0
24h
—
Growth
117d
Active
TIGITKeytrudaImmunotherapyCancer drugsClinical trials